Durability of DLQI Improvements Among Patients With Moderate to Severe Plaque Psoriasis Treated With Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin 2020, 4 (6), s80. https://doi.org/10.25251/skin.4.supp.80.